Investor FAQs

Show all


Immune Design was founded in 2008.
Immune Design was incorporated in the state of Delaware in February 2008.
1616 Eastlake Ave. E., Suite 310
Seattle, Washington  98102
Phone: (206) 682-0645
You can view our Board of Directors by visiting the Board of Directors section of our website.
You can view our management team by visiting the Management Team section of our website.
December 31st
Ernst & Young LLP
Immune Design is traded on the NASDAQ Global Market under the symbol “IMDZ”.
Immune Design went public in July, 2014.
Shares can be purchased through a stockbroker of your choice.
Immune Design does not offer a direct stock purchase plan.
Currently, Immune Design does not offer a dividend or a dividend reinvestment program.
45252L 103
Immune Design’s transfer agent is Computershare Trust Company, N.A. (CTC). You can find more information about how to contact CTC at:
Because Immune Design is a public company a stock certificate is not needed to represent your ownership in the company, but you can still request one. Please contact our transfer agent at: The company can look up your records and make any necessary adjustments. There is a fee involved for replacing lost certificates.
You must send both your old and new addresses to our transfer agent, Computershare Trust Company,, by U.S. mail. Each stockholder in question must sign the request for an address change.
Quarterly & Annual Reports and other investor materials, when available, can be found in Financials & Filings in the Investor Relations section of our corporate website.  Additionally, all SEC filings can also be accessed directly from the SEC at
You can view our recent press releases by visiting the News section of our website.
For media inquiries please send an email to
You can view information on our technology platform and programs by visiting the Pipeline section of our website.
For investor related questions please send an email to
Please use the Email Alerts link, to be added to the Immune Design distribution list.
Please send an email to